This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB09013/identifier/kegg-drug/
n2http://linked.opendata.cz/resource/drugbank/drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB09013/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
n11http://linked.opendata.cz/resource/drugbank/drug/DB09013/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB09013
rdf:type
n3:Drug
n3:description
Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
n3:generalReferences
# Reichl S, Muller-Goymann CC: The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride. Int J Pharm. 2003 Jan 2;250(1):191-201. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12480285
n3:group
experimental
n3:indication
Used in the management of open angle glaucoma. PMID: 12480285.
owl:sameAs
n7:DB09013
dcterms:title
Befunolol
adms:identifier
n10:D07496 n11:Befunolol n12:DB09013
n3:patent
n8:3853923
n3:synonym
(RS)-1-{7-[2-hydroxy-3-(propan-2-ylamino)propoxy]- 1-benzofuran-2-yl}ethanone
n3:salt
n3:IUPAC-Name
n4:271B64BA-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B64C0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B64BF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B64BC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B64BD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B64BE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B64B8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B64B6-363D-11E5-9242-09173F13E4C5 n4:271B64B9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B64B7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B64C6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B64C7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B64C1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B64C2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B64C4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B64C3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B64C5-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
39552-01-7
n3:Bioavailability
n4:271B64CC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B64CE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B64CF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B64D0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B64CB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B64CA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B64CD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B64BB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B64C8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B64C9-363D-11E5-9242-09173F13E4C5